



Ziyuanyuan Holdings Group Limited

紫元元控股集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8223)

**THIRD QUARTERLY RESULTS ANNOUNCEMENT
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2021**

**CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG
LIMITED (THE “STOCK EXCHANGE”)**

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement, for which the directors (the “**Directors**”) of Ziyuanyuan Holdings Group Limited (the “**Company**”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the “**GEM Listing Rules**”) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

The board of Directors (the “**Board**”) hereby announces the unaudited condensed consolidated financial results of the Company and its subsidiaries (the “**Group**”) for the three months and nine months ended 30 September 2021, together with the comparative unaudited figures for the corresponding period in 2020, as follows:

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the three months and nine months ended 30 September 2021

	Notes	Three months ended		Nine months ended	
		30.9.2021	30.9.2020	30.9.2021	30.9.2020
		RMB'000	RMB'000	RMB'000	RMB'000
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Revenue					
Finance leasing income		11,210	13,036	36,888	41,910
Interest income from loan receivables		178	160	704	1,133
Income from postpartum care services		13,478	832	36,937	832
Income from trading of medical equipments and consumables		2,006	–	4,786	–
Total revenue	3	26,872	14,028	79,315	43,875
Bank interest income		35	11	180	34
Other gains and losses	4	933	32	3,073	238
Staff costs	7	(8,965)	(3,477)	(25,261)	(9,687)
Impairment losses under expected credit loss (“ECL”) model, net of reversal		(308)	100	(3,847)	(7,000)
Other operating expenses		(15,875)	(3,870)	(42,774)	(10,893)
Finance costs	5	(2,295)	(2,122)	(6,025)	(7,143)
Profit before income tax		397	4,702	4,661	9,424
Income tax expenses	6	(19)	(10)	(237)	506
Profit and total comprehensive income for the period	7	378	4,692	4,424	9,930
Profit and total comprehensive income for the period attributable to:					
Owners of the Company		12	4,661	3,877	9,899
Non-controlling interests		366	31	547	31
		378	4,692	4,424	9,930
Earnings per share for profit attributable to owners of the Company during the period					
– Basic and diluted (RMB cents)	9	0.003	1.165	0.969	2.475

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the nine months ended 30 September 2021

	Attributable to owners of the Company						Non-controlling interests	Total
	Share capital	Share premium	Capital and other reserves	Statutory reserves	Retained profits	Total		
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At 1 January 2021 (audited)	33,839	73,551	133,023	8,817	53,138	302,368	944	303,312
Profit and total comprehensive income for the period	–	–	–	–	3,877	3,877	547	4,424
Dividends to shareholders of the Company (Note 8)	–	(8,333)	–	–	–	(8,333)	–	(8,333)
Dividends to non-controlling interests	–	–	–	–	–	–	(632)	(632)
Acquisition of subsidiaries	–	–	–	–	–	–	3,262	3,262
At 30 September 2021 (unaudited)	<u>33,839</u>	<u>65,218</u>	<u>133,023</u>	<u>8,817</u>	<u>57,015</u>	<u>297,912</u>	<u>4,121</u>	<u>302,033</u>
At 1 January 2020 (audited)	33,839	84,435	133,023	7,590	41,384	300,271	–	300,271
Profit and total comprehensive income for the period	–	–	–	–	9,899	9,899	31	9,930
Dividends to shareholders of the Company (Note 8)	–	(10,884)	–	–	–	(10,884)	–	(10,884)
Acquisition of a subsidiary	–	–	–	–	–	–	714	714
At 30 September 2020 (unaudited)	<u>33,839</u>	<u>73,551</u>	<u>133,023</u>	<u>7,590</u>	<u>51,283</u>	<u>299,286</u>	<u>745</u>	<u>300,031</u>

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. BASIS OF PREPARATION

The condensed consolidated financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards (“**HKFRSs**”) issued by the Hong Kong Institute of Certified Public Accountants (the “**HKICPA**”) as well as with the applicable disclosure requirements of Chapter 18 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited.

2. PRINCIPAL ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values, as appropriate.

Other than additional accounting policies resulting from application of amendments to HKFRSs and application of certain accounting policies which became relevant to the Group, the accounting policies and method of computation used in the condensed consolidated financial statements for the nine months ended 30 September 2021 are the same as those presented in the Group’s annual financial statements for the year ended 31 December 2020.

Application of amendments to HKFRSs

In the current period, the Group has applied the following amendments to HKFRSs issued by the HKICPA, for the first time, which are mandatorily effective for the annual period beginning on or after 1 January 2021 for the preparation of the Group’s condensed consolidated financial statements:

Amendments to HKAS 39, HKFRS 4, HKFRS 7,
HKFRS 9 and HKFRS 16

Interest Rate Benchmark Reform – Phase 2

The application of the amendments to HKFRSs in the current period has had no material impact on the Group’s financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

3. REVENUE

Revenue for the period represents finance leasing income, interest income on loan receivables received and receivable arising from the finance leasing activities, income from postpartum care services and income from trading of medical equipments and consumables in the PRC. The amounts of each significant category of revenue recognised in revenue during the period are as follows:

	Three months ended		Nine months ended	
	30.9.2021	30.9.2020	30.9.2021	30.9.2020
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Finance leasing income	11,210	13,036	36,888	41,910
Interest income from loan receivables	178	160	704	1,133
Income from postpartum care services	13,478	832	36,937	832
Income from trading of medical equipments and consumables	2,006	—	4,786	—
	<u>26,872</u>	<u>14,028</u>	<u>79,315</u>	<u>43,875</u>

4. OTHER GAINS AND LOSSES

	Three months ended		Nine months ended	
	30.9.2021	30.9.2020	30.9.2021	30.9.2020
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Gain on investment of structured deposits	489	142	1,241	540
Government subsidies	436	—	1,728	—
Exchange gain (loss), net	4	(111)	80	(303)
Others	4	1	24	1
	<u>933</u>	<u>32</u>	<u>3,073</u>	<u>238</u>

5. FINANCE COSTS

	Three months ended		Nine months ended	
	30.9.2021	30.9.2020	30.9.2021	30.9.2020
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Interests on bank borrowing	1,949	1,188	4,622	3,530
Imputed interests on interest-free deposits from finance lease customers	26	721	381	2,921
Interests on lease liabilities	320	213	1,022	692
	<u>2,295</u>	<u>2,122</u>	<u>6,025</u>	<u>7,143</u>

6. INCOME TAX EXPENSES

	Three months ended		Nine months ended	
	30.9.2021	30.9.2020	30.9.2021	30.9.2020
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
The charge (credit) comprises:				
Current tax				
– PRC Enterprise Income Tax	362	(500)	1,070	1,708
– Over provision in prior year	–	–	(489)	–
	<u>362</u>	<u>(500)</u>	<u>581</u>	<u>1,708</u>
– Withholding tax levied on dividend declared of a PRC subsidiary	–	–	500	600
Deferred tax	(343)	510	(844)	(2,814)
	<u>19</u>	<u>10</u>	<u>237</u>	<u>(506)</u>

No provision for Hong Kong Profits Tax has been made in the condensed consolidated financial statements as the Group's operation in Hong Kong had no assessable income during both periods.

Under the Enterprise Income Tax Law of PRC (the “EIT Law”) and the Implementation Regulation of the EIT Law, the subsidiaries in the PRC are subject to the tax rate of 25% during the reporting period. For the nine months ended 30 September 2021, certain PRC subsidiaries were eligible to be classified as small enterprises by the local bureau. The first RMB1,000,000 assessable profits is taxed at 2.5% and assessable profits above RMB1,000,000 and below RMB3,000,000 is taxed at 10%.

Withholding tax has been provided for the current period in the condensed consolidated financial statements.

7. PROFIT FOR THE PERIOD

Profit for the period has been arrived at after charging (crediting):

	Three months ended		Nine months ended	
	30.9.2021	30.9.2020	30.9.2021	30.9.2020
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Directors' emoluments	464	382	1,183	1,261
Other staff costs				
– Salaries, allowances and other staff benefits	7,897	3,038	22,416	8,900
– Staffs' retirement benefit scheme contributions	1,184	532	3,263	602
Total staff costs	9,545	3,952	26,862	10,763
Less: staff costs recognised as research and development costs in other operating expenses	(580)	(475)	(1,601)	(1,076)
Staff costs recognised in profit or loss	8,965	3,477	25,261	9,687
Amortisation of intangible assets	260	–	779	–
Covid-19-related rent concessions	–	–	–	(484)
Depreciation of property, plant and equipment	1,348	157	3,925	377
Depreciation of right-of-use assets	3,080	1,020	8,582	3,060
Property, plant and equipment written off	–	–	–	1
Research and development costs recognised as an expense (included in other operating expenses)	606	496	1,649	1,184
Short-term leases payments	1,550	288	4,505	288

8. DIVIDENDS

During the current period, a final dividend of HK2.5 cents (nine months ended 30 September 2020: HK3 cents) per share in respect of the year ended 31 December 2020 was declared to the owners of the Company. The aggregate amounts of the final dividend declared and paid were HK\$10,000,000 (equivalent to RMB8,333,000) (nine months ended 30 September 2020: HK\$12,000,000 (equivalent to RMB10,884,000)).

The directors of the Company do not recommend the payment of an interim dividend in respect of the nine months ended 30 September 2021 (nine months ended 30 September 2020: Nil).

9. EARNINGS PER SHARE

The calculation of basic earnings per share attributable to owners of the Company is based on the following data:

	Three months ended		Nine months ended	
	30.9.2021	30.9.2020	30.9.2021	30.9.2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Earnings:				
Earnings for the purpose of basic earnings per share				
Profit for the period attributable to owners of the Company for the purpose of basic earnings per share (RMB'000)	<u>12</u>	<u>4,661</u>	<u>3,877</u>	<u>9,899</u>
Number of shares:				
Weighted average number of ordinary shares for the purpose of basic earnings per share ('000)	<u>400,000</u>	<u>400,000</u>	<u>400,000</u>	<u>400,000</u>

No diluted earnings per share are presented as there were no potential dilutive ordinary shares in issue during the three months and nine months ended 30 September 2020 and 2021.

MANAGEMENT DISCUSSION AND ANALYSIS

The Board of Directors of the Company announces the unaudited condensed consolidated quarterly results of the Group for the nine months ended 30 September 2021 together with the corresponding comparative figures.

BUSINESS REVIEW

For the nine months ended 30 September 2021, the Group is principally engaged in provision of medical equipment finance leasing services, maternal and child postpartum care industry services and trading of medical equipments and consumables business in the PRC.

Finance leasing services

For the nine months ended 30 September 2021, the Group has been focusing on provision of finance leasing services to SMEs customers in the medical equipment industry in various provinces, municipalities, and autonomous regions in the PRC, where the Group has established connections with industry players and gained operational expertise. The finance lease offered by the Group comprises direct finance leasing and sale-leaseback. The Group provided services to approximately 2,960 SMEs customers across 30 provinces, municipalities and autonomous regions in the PRC as at 30 September 2021. The Group derived a revenue of RMB37.6 million from the finance leasing services for the nine months ended 30 September 2021.

Maternal and child postpartum care industry services

Postpartum confinement (坐月) is a traditional Chinese custom, which allows women to rest fully after giving birth, and to recover through diet. It is said that it is the best time for women to improve their physical well-being. Hence, centres for the provision of postpartum care services (月子中心) had emerged.

On 27 November 2020, the Group entered into the equity transfer agreement with independent third parties to purchase the entire equity interest in Guangzhou Sheng Cheng Dunnan Enterprise Management Co., Limited (“**Dunnan**”), a limited liability company incorporated in the PRC, with the consideration of RMB31 million. Dunnan and its subsidiaries are engaged in the provision of postpartum care services in the PRC. The equity was transferred in February 2021.

On 4 December 2020, the Group entered into the equity transfer agreement with independent third parties to purchase 54% of equity share of Wuhan Jiaenbei Health Management Co. Ltd. (“**Jiaenbei**”), a limited liability company incorporated in the PRC with consideration of RMB3.24 million. Jiaenbei is engaged in provision of postpartum care service in the PRC. The equity was transferred in January 2021.

As at 30 September 2021, the Group has 6 postpartum care centres in the PRC, which provide postpartum care services, consisting of four major areas of (i) health care for postpartum mothers and newborn babies; (ii) dietary and nutrition for postpartum mothers; (iii) recovery and beauty for postpartum mothers; and (iv) intellectual development for newborn babies. The Group derived a revenue of RMB36.9 million from the maternal and child postpartum care industry services for the nine months ended 30 September 2021.

Trading of medical equipments and consumables business

During the period, the Group having started the operation of trading of medical equipments and consumables. The Group derived a revenue of RMB4.8 million from trading of medical equipments and consumables business for the nine months ended 30 September 2021.

FUTURE PROSPECTS

In the current market environment of the PRC, SMEs face challenges on the path of development due to high operational and financing costs. In recent years, the People's Bank of China enhanced its policy support to major fields including SMEs and fragile aspects of domestic economy and devoted greater effort in procuring financial institutions to provide proactive support to the financing of SMEs, all of which gave supportive measures to the finance leasing industry. The scale and number of SMEs in the PRC are gigantic and yet the finance leasing market got off to a late start. Along with the development of the financing lease and increasing demand in the financing market, the penetration of finance lease has been deepening constantly, paving the way of a promising outlook of the finance leasing market in the PRC.

Looking forward, the Group is still reasonably optimistic to sustain the core business given all the economic uncertainties with the outbreak of Covid-19. The Group will continue to seek for the best possible opportunities to grow the Group's business by leveraging current client base. After the pandemic, the healthcare industry will be a new economic breakthrough with significant value-added potentials. The Group initiated pre-emptive deployment of medical equipment leasing, medical equipment trading and related fields in order to capture pioneer opportunities and support the industrial upgrade of the medical and related industry.

The PRC government has gradually relaxed the one-child policy in recent years. In October 2015, the PRC announced the universal two-children policy to boost the country's stagnating population growth. As a result, the birth rate in the PRC had risen sharply. Between 2017 and 2018, the total number of second-child births was more than 16 million, accounting for 50% of the total birth population. According to a public research report in relation to postpartum care industry market demand and investment planning, the market size of postpartum care centres in the PRC has been increasing since 2010 and is estimated to reach approximately RMB29 billion by 2024, showing a positive prospect for the industry. Together with the increase in gross domestic product per capita in tier 1 and tier 2 cities in the PRC, and the PRC announced the implementation of the three-child policy in May 2021, the Group is expected to benefit from the robust outlook of the postpartum care centres. The maternal and child healthcare related services have a rigid demand and the overall market will continue to grow rapidly.

The Covid-19 epidemic had severely impacted the global economy, and in particular, the first quarter of 2020 for the PRC. Besides groceries and daily necessities, medical and healthcare products and services, the postpartum care services industry could also maintain its normal operations during such difficult times, which reflect the rigid demand of the postpartum care services in the PRC market. Given that the expected date of delivery of the newborn is fixed, parents are required to make pre-arrangements for postpartum care services. In light of the sudden outbreak of the global pandemic, it was found that many parents prefer to use postpartum care centres instead of hiring post-natal care worker (陪月)/maternity matron (月嫂), as health conditions of the latter is less guaranteed. Further, the healthcare of postpartum care centres has a complete range of nursing expertise and functions, which is incomparable to hiring a housekeeping helper to take care of household chores.

At present, the concentration of the postpartum care service industry is extremely low, which is a common phenomenon for an industry in its early stage of development. Due to the increasing wealth of the Chinese that is followed by increasing demand for better health and lifestyle, together with the favourable government policies in place, the next ten years is believed to be the golden decade for the development of the postpartum care service industry.

The Group believes maternal and child postpartum care industry services will be a good entry point to the healthcare industry. The Group will continue to explore potential opportunities to diversify our business and if appropriate, explore selective acquisition and partnership in order to strengthen the Group's revenue base and maximize both the return to the shareholders and the value of the Group. The Group has established Shenzhen Meijiaer Health Management Co., Ltd.* (深圳市美佳爾健康管理有限公司) in 2020, which focuses on the provision of maternal and child postpartum care industry services in the PRC. Currently, the Group will focus on developing its postpartum care business in the Southern China and Central China regions, and through acquisitions and opening of landmark flagship postpartum care centres, to increase its market share. The Group aims to provide one-stop services for mothers and infants through upstream and downstream linkage, ranging from postpartum care centres and training schools for maternity matron and nursery teachers, to maternal and infant e-commerce for the sales of maternal and infant products. The Group is committed to establishing a comprehensive maternal and infant one-stop-shop.

Currently, the Group will focus on developing its maternal and child postpartum care industry services in the Southern China and Central China regions, and through acquisitions and opening of landmark flagship postpartum care centres, to increase its market share. In tier 1 cities, the high-end postpartum care centres is gradually becoming saturated, and is facing intense market competition. Therefore, the Group has shifted its target to mid-end brands in tier 1 cities, focusing on middle-class consumers.

The Group plans to enhance its competitive edge by exploring opportunities with local hospitals to provide pregnant women with convenient appointment booking and treatment channels, and to resolve the difficulty for pregnant women to make a reservation in large hospitals, in addition to services provided by the postpartum care centres, creating a one-stop-shop platform for its customers.

FINANCIAL REVIEW

Revenue

Revenue consists of (i) finance leasing income and interest income from loan receivables in finance leasing services; (ii) postpartum care services income; and (iii) income from trading of medical equipments and consumables. For the nine months ended 30 September 2021, the Group's revenue increased by approximately RMB35.4 million or approximately 80.8% to approximately RMB79.3 million (nine months ended 30 September 2020: approximately RMB43.9 million). The increase in revenue for the nine months ended 30 September 2021 was mainly attributable to the (i) new postpartum care services income of RMB36.9 million contributed by the maternal and child postpartum care industry services; and (ii) new income from trading of medical equipments and consumables of RMB4.8 million, which offsetting the finance leasing income decreased from approximately RMB43.1 million for the nine months ended 30 September 2020 to approximately RMB37.6 million for the nine months ended 30 September 2021.

Staff cost

Staff costs include primarily Directors' remuneration, employee salaries, allowances and other staff benefits as well as employee retirement benefits scheme contributions. Staff costs increased from RMB9.7 million for the nine months ended 30 September 2020 to approximately RMB25.3 million for the nine months ended 30 September 2021. The increase was mainly attributable to (i) the increase in head count and staff salaries for existing staff during the period; (ii) the additional staff costs incurred by new maternal and child postpartum care business; and (iii) the PRC government had granted a deduction for the Group's contribution of social insurance funds for the nine months ended 30 September 2020 and there was no such deduction for the nine months ended 30 September 2021.

Impairment losses under expected credit loss ("ECL") model, net of reversal

The Group is not required to provide general provisions as commercial banks and other financial institutions which the China Banking Regulatory Commission regulates. The provisioning policies are based on the applicable accounting standards. The management assesses the measurement of ECL in relation to finance lease receivable and loan receivables. In determining the impairment of finance lease receivable and loan receivables, the management considers shared credit risk characteristics including industry types, historical past due information and lessees' creditworthiness for grouping, and assesses credit losses based on internal credit rating and on a forward looking basis with the use of appropriate models and assumptions relate to the economic inputs and the future macroeconomic conditions.

For the nine months ended 30 September 2021, an additional impairment loss of approximately RMB3.8 million (nine months ended 30 September 2020: approximately RMB7.0 million) was recognised due to the impact of Covid-19, which caused the increase in the customers' past due ratio.

Other operating expenses

Other operating expenses include primarily travelling expenses, depreciation of property, plant and equipment, depreciation of right-of-use assets, short-term leases payments, the operating expenses incurred by new maternal and child postpartum care business and the cost of new medical equipments and consumables sold.

Other operating expenses increased from approximately RMB10.9 million for the nine months ended 30 September 2020 to approximately RMB42.8 million for the nine months ended 30 September 2021. Thereinto, the other operating expenses for the postpartum care business increased from approximately RMB0.6 million for the nine months ended 30 September 2020 to approximately RMB23.1 million for nine months ended 30 September 2021, and the related increase was mainly induced by the newly-setup centres for the provision of postpartum care services at the end of 2020 and the beginning of 2021, resulting in (i) the miscellaneous expenses of postpartum care business increased from approximately RMB0.5 million for nine months ended 30 September 2020 to approximately RMB5.9 million for nine months ended 30 September 2021; (ii) depreciation of right-of-use assets for nine months ended 30 September 2021 was approximately RMB5.9 million (nine months ended 30 September 2020: Nil); (iii) short-term leases payments for nine months ended 30 September 2021 was approximately RMB4.0 million (nine months ended 30 September 2020: Nil); (iv) office expenses, water, electricity and property management fees for nine months ended 30 September 2021 was approximately RMB1.4 million (nine months ended 30 September 2020: Nil); and (vi) sales and marketing expenses was approximately RMB1.4 million (nine months ended 30 September 2020: Nil).

The other operating expenses for finance lease business increased from approximately RMB10.3 million for nine months ended 30 September 2020 to approximately RMB15.1 million for nine months ended 30 September 2021. For nine months ended 30 September 2021, the increase of the other operating expenses was mainly attributed to (i) the increase in depreciation of property, plant and equipment, resulting from hiring a new head office in Shenzhen, the PRC in the second half year of 2020 in order to develop the new business and accommodate the increase in number of staff, which increased from approximately RMB0.3 million for the nine months ended 30 September 2020 to approximately RMB3.0 million for the nine months ended 30 September 2021; (ii) the acceptance of business system at the end of 2020, the amortisation of intangible assets was approximately RMB0.8 million for the nine months ended September 2021 (the nine months ended September 2020: Nil); and (iii) the increase of business and staff leads to the cost of office supplies increased from approximately RMB0.7 million for the nine months ended 30 September 2020 to approximately RMB1.4 million for the nine months ended 30 September 2021.

The cost of new medical equipments and consumables sold for the nine months ended 30 September 2021 was approximately RMB4.6 million (nine months ended 30 September 2020: Nil).

Finance costs

Finance costs consist of (i) imputed interest expense on interest-free deposits from finance lease customers; (ii) interest on bank borrowing; and (iii) interests on lease liabilities. Finance costs decreased from approximately RMB7.1 million for the nine months ended 30 September 2020 to approximately RMB6.0 million for the nine months ended 30 September 2021. The decrease was mainly due to imputed interest expense on interest-free deposits from finance lease customers decreased from approximately RMB2.9 million for the nine months ended 30 September 2020 to approximately RMB0.4 million for the nine months ended 30 September 2021 as a result in the reduction in the amount of deposits from finance lease customers, which offsetting the interest on bank borrowing increased from approximately RMB3.5 million for the nine months ended 30 September 2020 to approximately RMB4.6 million for the nine months ended 30 September 2021.

Income tax expenses

The PRC enterprise income tax rate applicable to the Group's subsidiaries is 25%. For the nine months ended 30 September 2021, certain PRC subsidiaries were eligible to be classified as small enterprises by the local bureau. The first RMB1,000,000 assessable profits is taxed at 2.5% and assessable profits above RMB1,000,000 and below RMB3,000,000 is taxed at 10%.

Taxation consists of current tax and deferred tax. Income tax expenses of RMB0.2 million was recognised for the nine months ended 30 September 2021, compared to an income tax credit of RMB0.5 million was recognised for the nine months ended 30 September 2020. The PRC Enterprise Income Tax in the current tax decreased from approximately RMB1.7 million for the nine months ended 30 September 2020 to approximately RMB1.1 million for the nine months ended 30 September 2021 due to the decrease in net profit. In addition, an income tax credit of RMB0.8 million (nine months ended 30 September 2020: RMB2.8 million) in the deferred tax was recognised for the nine months ended 30 September 2021 due to the reversal of withholding tax for undistributed earnings of PRC subsidiaries and the increase in ECL provision.

Profit and total comprehensive income attributable to owners of the Company

For the nine months ended 30 September 2021 and 2020, the Group's profit and total comprehensive income attributable to owners of the Company was approximately RMB3.9 million and RMB9.9 million, respectively. The decrease of profit and total comprehensive income attributable to owners of the Company in the current period was mainly attributable to the increase in staff costs and other operating costs which offsetting (i) the increase in revenue and other gains and losses; and (ii) the decrease in impairment losses under ECL model, net of reversal and finance costs as compared to the corresponding period in 2020.

Dividend

On 25 March 2021, a final dividend, in the form of a cash dividend of HK2.5 cents per share in respect of the year ended 31 December 2020 has been proposed by the Board and was approved by the shareholders in the annual general meeting held on 10 May 2021.

The Board of Directors of the Company does not recommend the payment of an interim dividend in respect of the nine months ended 30 September 2021 (nine months ended 30 September 2020: Nil).

CAPITAL STRUCTURE

The Shares were successfully listed on the GEM of the Stock Exchange on 9 July 2018. There has been no change in the capital structure of the Group since then. The share capital of the Group only comprises ordinary Shares.

As at 30 September 2021, the Company's issued share capital was HK\$40,000,000 and the number of its issued ordinary Shares was 400,000,000.

COMPETING INTEREST

During the nine months ended 30 September 2021, none of the Directors or the controlling shareholders of the Company or their respective close associates (as defined in the GEM Listing Rules) is interested in any business which competes or is likely to compete, either directly or indirectly, with the business of the Group or has any conflicts of interest with the Group.

DEED OF NON-COMPETITION

The controlling shareholders of the Company, namely Mr. Zhang Junshen (through Hero Global), Mr. Zhang Junwei (through Icon Global), (the “**Controlling Shareholders**”) entered into a deed of non-competition dated 12 June 2018 (“**Deed of Non-competition**”) in favour of the Company (for itself and as trustee for each of its subsidiaries). For details of the Deed of Non-competition, please refer to the section headed “Relationship with Controlling Shareholders – Non-competition Undertaking” in the Prospectus. Each of the Controlling Shareholders has confirmed that none of them is engaged in, or interested in any business (other than the Group) which, directly or indirectly, competes or may compete with the business of the Group.

The independent non-executive Directors have also reviewed the status of compliance and confirmed that all the undertakings under the Deed of Non-competition have been complied with by each of the Controlling Shareholders since the nine months ended 30 September 2021 and up to the date of this announcement.

PURCHASE, SALES OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company’s listed securities since the nine months ended 30 September 2021 and up to the date of this announcement.

CORPORATE GOVERNANCE PRACTICES

The Company considers the maintenance of a high standard of corporate governance important to the continuous growth of the Group. The Company’s corporate governance practices are based on code provisions as set out in the Corporate Governance Code (the “**CG Code**”) as contained in Appendix 15 of the GEM Listing Rules. Other than the deviation from code provision A.2.1, the Company has adopted and complied with, where applicable, the CG Code to ensure that the Group’s business activities and decision-making processes are regulated in a proper and prudent manner.

Up to the date of this announcement, other than the deviation from code provision A.2.1, the Company complied with the provisions of the CG Code as set out in Appendix 15 to the GEM Listing Rules.

CODE PROVISION A.2.1

In accordance with the code provision A.2.1 of the CG Code, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. The Board is of the view that although Mr. Zhang Junshen is the chairman and the chief executive officer of the Company, this structure will not impair the balance of power and authority between the Board and the management of the Company. The balance of power and authority is ensured by the operations of the Board, which comprises experienced and high caliber individuals and meets regularly to discuss issues affecting operations of the Company. The Board believes that this structure is conducive to strong and consistent leadership, enabling the Group to make and implement decisions promptly and efficiently. The Board has full confidence in Mr. Zhang Junshen and believes that his appointment to the posts of chairman and chief executive officer is beneficial to the business prospects of the Company.

EVENT AFTER THE REPORTING PERIOD

The Directors are not aware of any significant event which had material effect on the Group subsequent to 30 September 2021 and up to the date of this announcement.

SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted Rules 5.48 to 5.67 of the GEM Listing Rules as its own code of conduct (“**Code of Conduct**”) regarding securities transactions by the Directors. The Company has confirmed, having made specific enquiry of the Directors, that all the Directors have complied with the Code of Conduct for the nine months ended 30 September 2021 and up to date of this announcement.

AUDIT COMMITTEE AND REVIEW OF QUARTERLY RESULTS

The Group has established an audit committee (the “**Audit Committee**”) pursuant to a resolution of the Directors passed on 12 June 2018 in compliance with Rules 5.28 to 5.33 of the GEM Listing Rules and with written terms of reference in compliance with the CG Code.

The Audit Committee currently consists of one of our non-executive Directors, namely Mr. Lyu Di and two of our independent non- executive Directors, namely Chan Chi Fung Leo and Mr. Lin Weibin and the chairman is Mr. Chan Chi Fung Leo, who holds the appropriate professional qualifications as required under Rules 5.05(2) and 5.28 of the GEM Listing Rules.

The Audit Committee has reviewed the unaudited condensed consolidated financial statements of the Group for the nine months ended 30 September 2021 and is of the opinion that the preparation of such statements complied with the applicable accounting standards, the requirements under the GEM Listing Rules and other applicable legal requirements, and that adequate disclosures had been made.

By order of the Board
Ziyuanyuan Holdings Group Limited
Zhang Junshen
Chairman and Chief Executive Officer

Hong Kong, 10 November 2021

As at the date of this announcement, the executive Directors are Mr. Zhang Junshen (Chairman and Chief Executive Officer) and Mr. Zhang Yong, the non-executive Director is Mr. Lyu Di and the independent non-executive Directors are Mr. Chan Chi Fung Leo, Mr. Chow Siu Hang and Mr. Lin Weibin.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for at least 7 days from the date of its publication and this announcement will also be published on the website of the Company at www.ziyygroup.com.